← Back to Clinical Trials
Recruiting NCT07509359

NCT07509359 Comparing Basilic and Cephalic Vein Approaches for Midline Catheter Placement in Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07509359
Status Recruiting
Phase
Sponsor Seoul National University Hospital
Condition Vascular Access Device Complications
Study Type INTERVENTIONAL
Enrollment 96 participants
Start Date 2026-04-01
Primary Completion 2026-04-08

Trial Parameters

Condition Vascular Access Device Complications
Sponsor Seoul National University Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 96
Sex ALL
Min Age 2 Years
Max Age 17 Years
Start Date 2026-04-01
Completion 2026-04-08
Interventions
Midline catheter placement via basilic veinMidline catheter placement via cephalic vein

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This prospective randomized controlled trial aims to compare basilic vein and cephalic vein approaches for midline catheter placement in pediatric patients undergoing general anesthesia. Participants aged 2 to 17 years who require midline catheter insertion will be randomly assigned 1:1 to either the basilic vein group or the cephalic vein group. The primary outcome is the clinical blood sampling success rate during the catheter dwell period, defined as successful aspiration of ≥2 mL of blood through the midline catheter at least once without additional venipuncture. Secondary outcomes include operator-rated difficulty, number of puncture attempts, first attempt cannulation success rate, vein diameter and depth, catheter dwell time, catheter-related complications, and patient satisfaction. A total of 96 participants (48 per arm) will be enrolled at Seoul National University Children's Hospital.

Eligibility Criteria

Inclusion Criteria: * Age 2-17 years undergoing general anesthesia * Midline catheter placement deemed necessary by attending anesthesiologist (≥1 of: expected ≥2 postop blood draws; expected blood loss ≥40% EBV; continuous antibiotic therapy; hospitalization ≥7 days; surgical team request) Exclusion Criteria: * Need for central venous catheter per surgical team * Coagulopathy * History of severe thrombosis * Other investigator-determined ineligibility

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology